Abiomed Announces Record Revenue of $20 Million for Second Quarter of Fiscal 2010

November 5, 2009 7:00 AM EST

-- U.S. Commercial Impella Revenue at $12.1 Million, Up 95% From Prior Year

DANVERS, Mass.--(BUSINESS WIRE)-- Abiomed, Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies, today announced second quarter fiscal 2010 revenue of $20 million.

Recent financial and operating highlights during the second quarter of fiscal 2010 include:

    --  U.S. commercial Impella revenue totaled $12.1 million, up 95% compared
        to revenue of $6.2 million in the second quarter of fiscal 2009. U.S.
        commercial reorders totaled $6.6 million, up 230% from $2.0 million in
        the second quarter of fiscal 2009.
    --  Worldwide Impella revenue was $13.2 million, up 26% compared to revenue
        of $10.5 million for the second quarter of fiscal 2009.
    --  Approximately 338 U.S. commercial patients were treated with Impella(R)
        2.5, 5.0 or LD, a 238% increase compared to approximately 100 commercial
        patients in the second quarter of fiscal 2009. A total of over 1,200
        U.S. commercial patients have been treated with Impella as of the end of
        the second quarter of fiscal 2010.
    --  An additional 50 U.S. hospitals purchased Impella 2.5 for commercial use
        during the quarter, bringing the total to 326 commercial customers.
    --  During the second quarter of fiscal 2010, there were 28 patients
        enrolled in the Protect II study, for a total of 290 patients completed,
        or 44% of the 654 patients required.
    --  Legacy revenue, which consists of non-Impella revenue, was $6.8 million
        or 28% lower than the second quarter of fiscal 2009.
    --  Gross margin for the quarter was 73% compared to 76% in the second
        quarter of fiscal 2009.
    --  The GAAP net loss was $7.7 million, or a loss of $0.21 per share,
        compared to a GAAP net loss of $6.3 million, or a loss of $0.18 per
        share for the second quarter of fiscal 2009.
    --  The non-GAAP net loss, after excluding stock-based compensation expense
        of $2.0 million and intangibles amortization expense of $0.4 million,
        was $5.3 million, or a loss of $0.14 per share, compared to the non-GAAP
        net loss of $2.5 million, or a loss of $0.08 per share, for the second
        quarter of fiscal 2009, after excluding stock-based compensation expense
        of $3.4 million and intangibles amortization expense of $0.4 million.
    --  Cash, cash equivalents plus short and long-term marketable securities
        totaled $52.3 million compared to $54.5 million at the end of the first
        quarter fiscal 2010, reflecting a cash burn for the second quarter of
        fiscal 2010 of $2.2 million, a decrease of 46% compared to $4.1 million
        during the second quarter of fiscal 2009, excluding proceeds of $42.0
        million from a stock offering.
    --  At TCT in September 2009, Abiomed announced the clinical data from
        USpella, the first U.S. multicenter registry of 181 Impella 2.5
        patients, demonstrating that Impella 2.5 is able to treat patients in
        the cath lab who were turned down by surgery and decrease their SYNTAX
        score. High-risk PCI and AMI patients treated with Impella 2.5 showed an
        improvement in ejection fraction.
    --  Also at TCT 2009, data released from the Academic Medical Center's MACH
        II three-year follow-up results revealed that patients in the Impella
        2.5 arm of the trial showed improved left ventricular function, cardiac
        output and quality of life.

Impella US Commercial Launch

                                                                             V%

                                                                             Growth

                  Q2'09       Q3'09      Q4'09       Q1'10       Q2'10       Q2'10

                                                                             vs.

                                                                             Q2'09

# of Patients
per                 100         160        261         341         338       238%
Quarter

Avg. # of
Patients            8           12         20          26          26        225%
Supported per
Week

# of
Hospitals           108         55         66          47          50        (-54%)
added
per Quarter

Total
Commercial        $ 6.2M      $ 6.7M     $ 9.1M      $ 10.5M     $ 12.1M     95%
Revenue

Reorder
Revenue
(Contribution     $ 2.0M      $ 3.0M     $ 4.9M      $ 6.4M      $ 6.6M      230%
to Total
Commercial
Revenue)

Total
Worldwide
Impella
Revenue           $ 10.5M     $ 8.8M     $ 11.2M     $ 12M       $ 13.2M     26%
(ROW,
Commercial &
Trial)

"In summary, in the U.S. since last fiscal second quarter, as compared to this quarter, Abiomed has doubled the commercial U.S. Impella revenue, tripled the number of patients in the quarter and tripled the reorder revenue number," said Michael R. Minogue, Chairman, President and Chief Executive Officer of Abiomed. "We have also cut our cash burn in half while ramping up our expanded U.S. field team, releasing new product enhancements and unveiling our most robust clinical data to date at the premier customer TCT meeting. We like our position and strategy and are confident in our people, technology and execution."

Abiomed today reaffirmed its previously issued full-year fiscal 2010 revenue guidance of growth in the range of 17% to 24% or revenues of $86 million to $91 million.

The Company will host a conference call on Thursday, November 5, 2009 at 8 a.m. ET to discuss its second quarter of fiscal 2010 results. Michael R. Minogue, Chairman, Chief Executive Officer and President, and Robert L. Bowen, Vice President and Chief Financial Officer, will host the conference call.

To listen to the call live, please tune into the webcast via http://investor.abiomed.com or dial 800.638.4930; the international number is 617.614.3944. The access participant code is 10095872. A replay of this conference call will be available beginning at 11 a.m. ET on November 5, 2009 through 11:59 p.m. ET on November 19, 2009. The replay phone number is 888.286.8010; the international number is 617.801.6888. The replay access code is 72639080.

ABOUT ABIOMED

Based in Danvers, Massachusetts, Abiomed, Inc., is a leading provider of medical devices that provide circulatory support to acute heart failure patients across the continuum of care in heart recovery. Our products are designed to enable the heart to rest, heal and recover by improving blood flow and/or performing the pumping of the heart. For additional information please visit: www.abiomed.com.

USE OF NON-GAAP MEASURES

In addition to financial measures prepared in accordance with generally accepted accounting principles (GAAP), this earnings announcement also contains non-GAAP financial measures of net loss and net loss per share, in each case excluding, where appropriate, stock-based compensation and intangibles amortization. We believe that the inclusion of these non-GAAP financial measures in this earnings announcement helps investors to gain a meaningful understanding of our core operating results and future prospects, and can also help investors who wish to make comparisons between us and other companies on both a GAAP and a non-GAAP basis, particularly with respect to stock based compensation expenses. The non-GAAP financial measures included in this earnings announcement are not meant to be considered superior to or a substitute for results of operations prepared in accordance with GAAP. In addition, the non-GAAP financial measures included in this earnings announcement may be different from, and therefore may not be comparable to, similar measures used by other companies. Although certain non-GAAP financial measures used in this release exclude the accounting treatment of stock based compensation expense and other items outlined in this release and above, these non-GAAP measures should not be relied upon independently, as they ignore the contribution to our operating results that is generated by the incentive and compensation effects of the underlying stock based compensation programs.

FORWARD-LOOKING STATEMENTS

This Release contains forward-looking statements, including statements regarding development of Abiomed's existing and new products, the Company's progress toward commercial growth, and future opportunities and expected regulatory approvals. The Company's actual results may differ materially from those anticipated in these forward-looking statements based upon a number of factors, including uncertainties associated with development, testing, regulatory approvals, anticipated future losses, complex manufacturing, high quality requirements, dependence on limited sources of supply, competition, technological change, government regulation, future capital needs and uncertainty of additional financing, and other risks and challenges detailed in the Company's filings with the Securities and Exchange Commission, including the Annual Report filed on Form 10-K and the most recently filed Quarterly Report on Form 10-Q. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this Release. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this Release or to reflect the occurrence of unanticipated events.

Abiomed, Impella, iPulse, BVS5000, AB5000, AbioCor and the Abiomed logo are all trademarks of Abiomed. Other company and product names may be trademarks of their respective owners.

Abiomed, Inc. and Subsidiaries

Condensed Consolidated Balance Sheets

(in thousands, except share data)

                                             September 30, 2009   March 31, 2009

                                             (unaudited)

ASSETS

Current assets:

Cash and cash equivalents                    $ 2,782              $ 1,785

Short-term marketable securities               49,548               55,394

Accounts receivable, net                       13,403               15,724

Inventories                                    14,111               14,777

Prepaid expenses and other current assets      992                  809

Total current assets                           80,836               88,489

Property and equipment, net                    7,540                7,792

Intangible assets, net                         3,996                4,359

Goodwill                                       40,310               31,295

Long-term marketable securities                ---                  3,721

Other assets                                   302                  302

Total assets                                 $ 132,984            $ 135,958

LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities:

Accounts payable                             $ 5,239              $ 5,550

Accrued expenses                               9,654                10,818

Deferred revenue                               1,237                1,211

Total current liabilities                      16,130               17,579

Long-term deferred tax liability               2,554                2,086

Other long-term liabilities                    410                  310

Total liabilities                              19,094               19,975

Commitments and contingencies

Stockholders' equity:

Class B Preferred Stock, $.01 par value        ---                  ---

Authorized - 1,000,000 shares; Issued and
outstanding - none

Common stock, $.01 par value                   375                  367

Authorized - 100,000,000 shares; Issued -
37,520,065 shares at September 30, 2009
and 36,736,843 shares at March 31, 2009;
Outstanding - 37,469,111 shares at
September 30, 2009 and 36,685,889 shares
at March 31, 2009

Additional paid-in-capital                     370,169              362,097

Accumulated deficit                            (259,425)            (243,991)

Treasury stock at cost - 50,954 at             (827)                (827)
September 30, 2009 and March 31, 2009

Accumulated other comprehensive income         3,598                (1,663)
(loss)

Total stockholders' equity                     113,890              115,983

Total liabilities and stockholders' equity   $ 132,984            $ 135,958

Abiomed, Inc. and Subsidiaries

Condensed Consolidated Statements of Operations

(Unaudited)

(in thousands, except share and per share data)

                                    Three Months Ended    Six Months Ended

                                    September 30,         September 30,

                                    2009       2008       2009        2008

Revenue:

Product                             $ 19,725   $ 19,777   $ 39,314    $ 36,047

Funded research and development       297        222        621         309

Total Revenue                         20,022     19,999     39,935      36,356

Costs and expenses:

Cost of product revenue excluding     5,446      4,793      10,518      10,420
amortization of intangibles

Research and development              6,786      6,850      12,769      12,994

Selling, general and                  14,816     13,898     30,783      27,412
administrative

Amortization of intangible assets     371        411        725         837

                                      27,419     25,952     54,795      51,663

Loss from operations                  (7,397)    (5,953)    (14,860)    (15,307)

Other income and expense:

Investment income (expense), net      53         (43)       97          201

Other (expense) income, net           (88)       (61)       (203)       80

                                      (35)       (104)      (106)       281

Loss before provision for income      (7,432)    (6,057)    (14,966)    (15,026)
taxes

Provision for income taxes            242        273        468         418

Net loss                            $ (7,674)  $ (6,330)  $ (15,434)  $ (15,444)

Basic and diluted net loss per      $ (0.21)   $ (0.18)   $ (0.42)    $ (0.46)
share

Weighted average shares               36,924     34,475     36,736      33,393
outstanding

    Source: Abiomed, Inc.

Related Categories

Press Releases

Stocks Mentioned

Add Your Comment

Name

Subject

Body

Verification can't see the text?
click here to refresh the image.
what's this?